The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
KIR3DL1 antikoerper, KIR3DL3 antikoerper, CD158E1 antikoerper, KIR antikoerper, KIR3DL1/S1 antikoerper, NKAT3 antikoerper, NKB1 antikoerper, NKB1B antikoerper, Kirl1 antikoerper, Kirl2 antikoerper, Krl1 antikoerper, killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 antikoerper, uncharacterized LOC100437736 antikoerper, killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 antikoerper, KIR3DL1 antikoerper, LOC100437736 antikoerper, Kir3dl1 antikoerper
Hintergrund
CD158e1, also known as NKB1, is a 70 kD member of the immunoglobulin superfamily that is expressed on a subset of natural killer cells and T cells at varying levels among individuals. NKB1 is a type I membrane protein containing two immunoglobulin C2-type domains. The interaction of NKB1 with specific HLA-B antigens on a target cell (the HLA-Bw4 allele, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.